Briacell Therapeutics Corp BCTX

$3.43 +0.02 (0.73%)

Valuation

Market cap
31,319,000
Revenue TTM
$0
Net income TTM
$-26,310,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
65,800
Avg volume
312,178
Day's range
$3.32 – $3.64
Shares out
8,700,000
Stochastic %K
9%
Beta
1.21
Analysts
Strong Buy
Price target
$40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...

Show more

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 921 1810
Website
https://briacell.com
Address
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news

Stocktwits

SmallCapGrowth Oct 23, 6:35 PM
🚀 $BCTX continues advancing its immunotherapy research. New ESMO 2026 biomarker findings highlight a potential avenue for understanding clinical outcomes in metastatic breast cancer. https://www.globenewswire.com/news-release/2026/10/23/3387183/0/en/briacell-announces-esmo-2026-poster-highlighting-circulating-immune-biomarker-associated-with-clinical-outcomes-in-metastatic-breast-cancer.html #BriaCell #BCTX
0 replies
SmallCapGrowth Oct 23, 5:24 PM
$BCTX at ESMO 2026! A pooled - Xtremepicks Alerts https://investorshangout.com/post/view?id=6849723
0 replies
SmallCapGrowth Oct 23, 5:12 PM
Whale Team : 📢 $BCTX at ESMO 2026! A pooled a... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=178071543 via @Investors_Hub
0 replies
Fergus20 Oct 23, 5:08 PM
$BCTX $MRK $MRNA this guy means $BCRX
1 replies
Biotechlineup Oct 23, 5:06 PM
$MRK $MRNA $BCTX Yes and that’s why a tiny micro micro cap with a platform that has a higher efficacy with minimal side effects, off shelf yet personalized at a fraction of the cost. This will be the true world wide public health miracle for cancer. Fantasy ? We will know in a couple of months when the phase 3 breast cancer trial reports interim results. Moderna’s vaccine a miracle which will be a commercial failure due to the 8 week delay, outrageous cost which insurance companies will not pay. Limited to certain subset.
0 replies
SmallCapGrowth Oct 23, 4:33 PM
📢 $BCTX at ESMO 2026! A pooled analysis of 111 patients found associations between changing immune biomarker levels and survival outcomes following immunotherapy. #BriaCell #Biotech NEWS: https://www.globenewswire.com/news-release/2026/10/23/3387183/0/en/briacell-announces-esmo-2026-poster-highlighting-circulating-immune-biomarker-associated-with-clinical-outcomes-in-metastatic-breast-cancer.html
0 replies
SmallCapGrowth Oct 23, 4:29 PM
BB's Stock Haven : 🚨 $BCTX News! BriaCell presents... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=178071473 via @Investors_Hub
0 replies
SmallCapGrowth Oct 23, 4:23 PM
🔬 New data for $BCTX! BriaCell highlights the potential of CAML PD-L1 monitoring to help assess treatment outcomes in metastatic breast cancer patients. https://www.globenewswire.com/news-release/2026/10/23/3387183/0/en/briacell-announces-esmo-2026-poster-highlighting-circulating-immune-biomarker-associated-with-clinical-outcomes-in-metastatic-breast-cancer.html $NWPG $NWPG $ECOX.X $RNWF $GRLT $ADHC #BCTX #Immunotherapy
0 replies